NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
October 02 2023 - 6:50AM
Business Wire
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces that Justin Hall, CEO and General
Counsel, will present a company overview and hold investor meetings
at the 8th Annual Dawson James Small Cap Growth Conference being
held Thursday, October 12, 2023 at the Wyndham Grand Harborside
Hotel in Jupiter, Fla.
“We are excited to showcase the innovative products in our
eyecare, skincare, and wound care business segments at this
upcoming conference,” said Mr. Hall. “I’ll be presenting our future
strategies to address the large market opportunities for the
Avenova®, DERMAdoctor® and PhaseOne® brands.”
Investors interested in arranging a meeting with NovaBay
management should contact Jody Cain at LHA Investor Relations. The
NovaBay corporate presentation can be access from the Presentation
page of the Investor Relations section of the Company’s
website.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare, skincare and wound care
products. NovaBay’s leading product Avenova® Antimicrobial Lid
& Lash Solution is often prescribed by eyecare professionals
for blepharitis and dry-eye disease and is also available directly
to consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 dermatologist-developed skincare
products through the DERMAdoctor website, well-known traditional
and digital beauty retailers, and international distributors.
NovaBay also manufactures and sells effective, yet gentle and
non-irritating wound care products. The PhaseOne® brand is
distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited. More information
about NovaBay is available here.
NovaBay Pharmaceuticals Forward-Looking Statements
]Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002622088/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024